Hypercholesterolemia. Disorders of lipoprotein metabolism and other lipidaemias
Conditions
Interventions
Intervention 1: Placebo capsule 400 mg 3 times a day treatment orally for one month. Intervention 2: Rheum Ribes 400 mg capsule 3 times a day treatments orally for one month.
Treatment - Drugs
Placebo capsule 400 mg 3 times a day treatment orally for one month
Rheum Ribes 400 mg capsule 3 times a day treatments orally for one month
Sponsors
Jahad Daneshgahi
Endocrinology & Metabolism Research Center
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 40 to 60 years, serum cholesterol above 100 mg/dl, confirmed type II diabetes at least for two years with fasting blood glucose above 150-250 mg/dl taking Metformin or Glibenclamid, HbA1c 7.5-10%, not taking any antihypercholesterolmic drug during past month, signing the written informed consent. Exclusion criteria: Insulin therapy, infectious diseases, severe kidney, liver, heart and pulmonary diseases, hypersensitivity to any drug, foot ulcer or gangrene, major depressive disorder, previous myocardial infarction, active cancer or previous cancer during past 5 years, history of alcohol consumption or cigarette smoking, pregnancy, breast feeding.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL cholesterol. Timepoint: Baseline and after one month. Method of measurement: The fasting serum LDL cholesterol concentration determined in blood sample by calculating HDL and total cholesterol level.;Blood glucose. Timepoint: Baseline and after one month. Method of measurement: The fasting serum glucose concentration determined in blood sample by glucose oxidase method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholesterol. Timepoint: Baseline and after one month. Method of measurement: The fasting serum total cholesterol level in blood sample by enzymatic oxidase method.;HDL. Timepoint: Baseline and after one month. Method of measurement: The fasting blood HDL level in blood sample by CDC designated comparison method.;Triglyceride. Timepoint: Baseline and after one month. Method of measurement: The fasting blood Triglyceride level in blood sample by enzymatic oxidase method.;SGOT. Timepoint: Baseline and after one month. Method of measurement: The fasting blood SGOT level in blood sample by DGKG enzymatic method.;SGPT. Timepoint: Baseline and after one month. Method of measurement: The fasting blood SGPT level by DGKG enzymatic method.;Creatinine. Timepoint: Baseline and after one month. Method of measurement: The fasting blood Creatinine level in blood sample by JAPH enzymatic method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHassan Fallah Huseini
Institute of Medicinal Plants, ACECR
Outcome results
None listed